Fortress Biotech Inc. (FBIO)

1.91 -0.12 (-5.911%)

IEX Real-Time Price

August 17, 2018 EST.

NASDAQ Capital Market : Healthcare

Prev Close 2.03

Price Open 2.01

Volume: 88,973

Avg Volume: 193,722

Market Cap: 103.79M

P/E Ratio -1.02

52 Wk Range 1.4101-5.54



FBIO Short Interest Statistics


Report Date
Float Share
Short Interest
Short Ratio
Short % to Float

2018-07-31
42.68M
732,437
6.35
1.72%

2018-07-13
42.68M
879,829
8.30
2.06%

2018-06-29
42.68M
938,671
8.13
2.20%

2018-06-15
42.68M
857,567
5.41
2.01%




FBIO Earning Report


Report Date
Fiscal Period
Announce Time
Estimated EPS(#)
Actual EPS
Surprise Dollar

2018-05-10
Q1 2018
N/A
-0.46 (1)
-0.49
-0.03

2018-05-09
Q1 2018
N/A
-0.46 (1)
0.00
0.00

2018-03-16
Q4 2017
N/A
-0.57 (1)
-0.21
0.36

2018-03-15
Q4 2017
N/A
-0.57 (1)
0.00
0.00

News

Checkpoint Therapeutics: Potential For A Near-Term Run Up (2018-08-14 10:58 SeekingAlpha)

Shares of Checkpoint Therapeutics ( CKPT ) have fallen by around 60% since the firms common stock began trading on the NASDAQ in June of last year. In the past, Ive been slightly biased against Fortress Biotech and its subsidiaries, whether due to pure skepticism, its controllin…

 


Statistics

Shares Outstanding: 54.34M

Top 15 Institution Percent: 12.30

Price To Sales: 0.58

Price To Book: 2.36

Revenue: 46.89M

Gross Profit: 46.38M

Cash: 156.22M

Debt: 63.62M

Return On Assets: -32.94

Return On Equity: -137.96

Profit Margin: -71.64

Price History

Beta: 0.10

50-day Moving Avg: 2.69

200-day Moving Avg: 3.68

YTD Change: -53.07

5-day Change: -9.91

1-month Change: -31.79

3-month Change: -47.81

6-month Change: -44.15

1-year Change: -55.48

Revenue Per Share: 1.00

Revenue Per Employee: 689500.00



Dividend

Dividend Yield: -

EX-Dividend Date: -

Dividend Rate: -


Company Profile

Name: Fortress Biotech Inc.

Exchange: NASDAQ Capital Market

Industry: Biotechnology

Sector: Healthcare

Website: http://www.fortressbiotech.com

Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing and commercializing pharmaceutical and biotechnology products.